MedTrace Logo

Arimoclomol in Sporadic Inclusion Body Myositis

NCT00769860 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-01-19

Study results available
· View outcomes & findings →

Summary

Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over 4 months of treatment.

Conditions

  • Inclusion Body Myositis

Interventions

DRUG

Arimoclomol

Arimoclomol 100 mg TID for 4 months

OTHER

Placebo

Placebo for 4 months

Sponsors & Collaborators

  • Richard Barohn, MD

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00769860 on ClinicalTrials.gov